BAK1 and chronic myelogenous leukemia, BCR-ABL1 positive: It also has been shown to target BAK and p53 directly in Ewing sarcoma/primitive neuro‐ectodermal tumour,84 and it contributes to the increased proliferation and decreased apoptosis observed in chronic myeloid leukaemia, by repressing the activity of BAK1.85